12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Omecamtiv mecarbil: Phase IIb started

Cytokinetics and partner Amgen began a double-blind, placebo-controlled, international Phase IIb trial to evaluate 3 doses of IV omecamtiv mecarbil in about 600 patients. Amgen has exclusive, ex-Japanese rights...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >